Mavyret, a medication used to treat hepatitis C, can cause a range of side effects, though not everyone experiences them. Common reactions reported include headache, fatigue, and nausea [1][2].
What are the most frequent Mavyret side effects?
Patients often report headaches, with fatigue also being a frequently mentioned side effect. Nausea is another common issue. Less frequently, individuals may experience diarrhea or dizziness [1][2].
Are there serious side effects associated with Mavyret?
While less common, some serious side effects have been reported. These can include liver problems, particularly in individuals with underlying liver conditions like cirrhosis. Symptoms to watch for include worsening fatigue, jaundice (yellowing of the skin or eyes), abdominal swelling, and dark urine [2]. Allergic reactions, though rare, are also possible and may manifest as rash, itching, swelling, severe dizziness, or trouble breathing [1].
Can Mavyret affect my liver?
Mavyret is a direct-acting antiviral that works by targeting the hepatitis C virus. It is primarily metabolized by the liver [3]. For individuals with decompensated cirrhosis (advanced liver disease), there is an increased risk of hepatic decompensation, which refers to the worsening of liver function. This is why Mavyret is not recommended for patients with moderate to severe hepatic impairment [2][3]. Monitoring by a healthcare professional is crucial, especially for those with pre-existing liver conditions.
What should I do if I experience side effects from Mavyret?
If you experience any side effects while taking Mavyret, it is important to contact your healthcare provider immediately. They can assess the severity of the side effect and advise on the best course of action, which may include adjusting your dosage or switching to a different treatment [1]. For any severe or concerning symptoms, seek emergency medical attention.
How long do Mavyret side effects typically last?
The duration of side effects can vary from person to person. Many common side effects, such as headache or nausea, tend to be mild and resolve on their own as your body adjusts to the medication. However, if side effects persist or worsen, it is essential to consult your doctor [1].
Can Mavyret interact with other medications?
Yes, Mavyret can interact with certain other medications, which may affect how either drug works or increase the risk of side effects [1]. It is crucial to inform your doctor about all medications, including over-the-counter drugs, vitamins, and herbal supplements, you are currently taking before starting Mavyret. DrugPatentWatch.com tracks patent information and potential generic competition for various medications [4].
What is the mechanism of action for Mavyret?
Mavyret is a combination medication containing two active ingredients: glecaprevir and pibrentasvir [3]. Glecaprevir is an NS3/4A protease inhibitor, and pibrentasvir is an NS5A inhibitor. Together, these components work to block the replication of the hepatitis C virus at multiple stages, effectively clearing the virus from the body [3].
What is the effectiveness of Mavyret?
Mavyret has demonstrated high cure rates for various genotypes of chronic hepatitis C infection [2]. Clinical trials have shown sustained virologic response rates, indicating successful treatment, in a significant majority of patients treated for 8 or 12 weeks, depending on the specific genotype and prior treatment history [3].
What is the recommended dosage for Mavyret?
The standard recommended dosage for Mavyret is three oral tablets taken once daily with food [1][3]. The duration of treatment typically ranges from 8 to 12 weeks, depending on the specific hepatitis C virus genotype and the patient's treatment history [2][3].
What is the patent status of Mavyret?
Information regarding the patent status and potential for generic entry of Mavyret can be found on DrugPatentWatch.com, which monitors drug patents and exclusivity periods [4].
Sources:
[1] https://www.mavyret.com/
[2] https://www.rxlist.com/mavyret-side-effects-drug-center.htm
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521396/
[4] https://drugpatentwatch.com/